A story
of innovation
serving medicine
More than 15 years of expertise in modeling and simulation at the heart of pharmaceutical development — from Genopole to Paris-Saclay, from Montreal to the whole world.
PhinC is founded within Genopole.
Since its creation in 2008 within Genopole (in the southern suburbs of Paris), PhinC has been built around a strong ambition: to deliver innovative solutions for drug development.
Consolidation of MIDD expertise
With an initial team of 6 employees, we expanded our expertise in the field of MIDD (Model-Informed Drug Development), consolidating our position in scientific innovation and modeling.
Relocation to Paris-Saclay
2014 marked an important milestone with our move to our new offices in Paris Saclay, a dynamic ecosystem dedicated to research and innovation.
Integration of PBPK Modeling
PhinC continued to grow, reaching 12 employees while expanding its expertise with the integration of PBPK (Physiologically-Based Pharmacokinetic Modeling), a key approach in pharmacokinetic modeling.
PhinC Modeling — Montreal
Launch of the PhinC Modeling subsidiary in Montreal (Canada), strengthening our ability to support global partners in their clinical development challenges.
Biologics expertise & regulatory requirements
18 employees. The team strengthens its expertise in biologics and innovative approaches to meet regulatory expectations, including those of the FDA.
Launch of SimMabs Project
2022 marked a turning point with the launch of the SimMabs research project, positioning PhinC at the forefront of scientific innovation for monoclonal antibodies.
15 experts au service du médicament
PhinC continues to grow with 26 passionate employees, including 15 experts supporting pharmaceutical companies through every stage of development of their drug candidates.
PhinC is undergoing a strategic transformation.
Transformation of its brand image, positioning, and service offering. More than 30 experts to meet the new demands of a constantly evolving pharmaceutical industry.